2013•Novelty in biomedicineOpen access

Assessment of antibiotic resistance pattern in Acinetobacter baumannii carrying bla oxA type genes isolated from hospitalized patients

Hossein Goudarzi, Masoumeh Douraghi, Zohreh Ghalavand, Mehdi Goudarzi

Open full text 25 citations

Abstract

Background & Objective: Acinetobacter baumannii is a Gram-negative coccobacillus and one of the most opportunistic pathogens responsible for serious infections in hospitalized patients. Materials and Methods: During a 12 months study, 221 clinical isolates and 22 environmental Acinetobacter baumannii isolates were collected. In vitro susceptibility of Acinetobacter baumannii isolates to 13 antimicrobial agents: amikacin; cefepime; ceftazidime; ciprofloxacin; meropenem; piperacillin/tazobactam; sulfamethoxazole/ trimethoprim; imipenem; tigecycline; colistin; gentamycin; ceftriaxone; levofloxacin was performed by the disk diffusion method. Also Minimum Inhibitory Concentration (MICs) of imipenem; levofloxacin and cefepime was performed by the E-test according to Clinical and Laboratory Standards Institute (CLSI) criteria. blaOXA-23, blaOXA24, blaOXA-58, blaOXA-51 genes were detected by polymerase chain reaction and sequencing. Results: The result of antimicrobial susceptibility test of clinical isolates by the disk diffusion method revealed that all strains of Acinetobacter baumannii were resistant to piperacillin/tazobactam. The rates of resistance to the majority of antibiotics tested varied between 69% and 100 %, with the exception of tigecycline and colistin. Of 221 isolates tested 99(44.8%) were XDR. All strains carried a blaOXA-51-like gene. blaOXA-23 gene was the most prevalent among blaOXA-types Conclusion: Colistin and tigecycline can be effective drugs for treatment of Acinetobacter baumannii infections. Continuous Surveillance for Acinetobacter baumannii multidrug-resistant strains is necessary to prevent the

About this research paper

What this paper is about

Background & Objective: Acinetobacter baumannii is a Gram-negative coccobacillus and one of the most opportunistic pathogens responsible for serious infections in hospitalized patients. Materials and Methods: During a 12 months study, 221 clinical isolates and 22 environmental Acinetobacter baumannii isolates were collected. In vitro susceptibility of Acinetobacter baumannii isolates to 13 antimicrobial agents: amikacin; cefepime; ceftazidime; ciprofloxacin; meropenem; piperacillin/tazobactam; sulfamethoxazole/ trimethoprim; imipenem; tigecycline; colistin; gentamycin; ceftriaxone; levofloxacin was performed by the disk diffusion method. Also Minimum Inhibitory Concentration (MICs) of imipenem; levofloxacin and cefepime was performed by the E-test according to Clinical and Laboratory Standards Institute (CLSI) criteria. blaOXA-23, blaOXA24, blaOXA-58, blaOXA-51 genes were detected by polymerase chain reaction and sequencing. Results: The result of antimicrobial susceptibility test of clinical isolates by the disk diffusion method revealed that all strains of Acinetobacter baumannii were resistant to piperacillin/tazobactam. The rates of resistance to the majority of antibiotics tested varied between 69% and 100 %, with the exception of tigecycline and colistin. Of 221 isolates tested 99(44.8%) were XDR. All strains carried a blaOXA-51-like gene. blaOXA-23 gene was the most prevalent among blaOXA-types Conclusion: Colistin and tigecycline can be effective drugs for treatment of Acinetobacter baumannii infections. Continuous Surveillance for Acinetobacter baumannii multidrug-resistant strains is necessary to prevent the

Why it matters

OpenAlex reports 25 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Background & Objective: Acinetobacter baumannii is a Gram-negative coccobacillus and one of the most opportunistic pathogens responsible for serious infections in hospitalized patients. Materials and Methods: During a 12 months study, 221 clinical isolates and 22 environmental Acinetobacter baumannii isolates were collected. In vitro susceptibility of Acinetobacter baumannii isolates to 13 antimicrobial agents: amikacin; cefepime; ceftazidime; ciprofloxacin; meropenem; piperacillin/tazobactam; sulfamethoxazole/ trimethoprim; imipenem; tigecycline; colistin; gentamycin; ceftriaxone; levofloxacin was performed by the disk diffusion method. Also Minimum Inhibitory Concentration (MICs) of imipenem; levofloxacin and cefepime was performed by the E-test according to Clinical and Laboratory Standards Institute (CLSI) criteria. blaOXA-23, blaOXA24, blaOXA-58, blaOXA-51 genes were detected by polymerase chain reaction and sequencing. Results: The result of antimicrobial susceptibility test of clinical isolates by the disk diffusion method revealed that all strains of Acinetobacter baumannii were resistant to piperacillin/tazobactam. The rates of resistance to the majority of antibiotics tested varied between 69% and 100 %, with the exception of tigecycline and colistin. Of 221 isolates tested 99(44.8%) were XDR. All strains carried a blaOXA-51-like gene. blaOXA-23 gene was the most prevalent among blaOXA-types Conclusion: Colistin and tigecycline can be effective drugs for treatment of Acinetobacter baumannii infections. Continuous Surveillance for Acinetobacter baumannii multidrug-resistant strains is necessary to prevent the

Key concepts: Tigecycline, Acinetobacter baumannii, Cefepime, Colistin, Microbiology, Imipenem, Amikacin, Meropenem

Related papers

Back to paper searchBrowse research topicsOriginal source
Assessment of antibiotic resistance pattern in Acinetobacter baumannii carrying bla oxA type genes isolated from hospitalized patients — Research Paper | ScholarLens